Comment on "Pre-hospital antiplatelet medication use on COVID-19 disease severity".
作者信息
Nadeem Arsalan, Ejaz Zoya
机构信息
Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan.
出版信息
Heart Lung. 2022 Sep-Oct;55:164-165. doi: 10.1016/j.hrtlng.2022.04.020. Epub 2022 May 2.
Abstract
摘要
相似文献
1
Comment on "Pre-hospital antiplatelet medication use on COVID-19 disease severity".关于“院前使用抗血小板药物对新冠病毒疾病严重程度的影响”的评论
Heart Lung. 2022 Sep-Oct;55:164-165. doi: 10.1016/j.hrtlng.2022.04.020. Epub 2022 May 2.
2
Comment on "Pre-hospital antiplatelet medication use on COVID-19 disease severity".关于“新冠疫情下院前抗血小板药物使用对疾病严重程度的影响”的评论
Heart Lung. 2023 Mar-Apr;58:256-257. doi: 10.1016/j.hrtlng.2022.09.004. Epub 2022 Sep 14.
3
Antiplatelet Therapy in Patients With COVID-19-More Is Less?新冠病毒肺炎患者的抗血小板治疗——多即少？
JAMA. 2022 Jan 18;327(3):223-224. doi: 10.1001/jama.2021.23866.
4
The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19.抗血小板药物在新型冠状病毒肺炎动脉血栓预防中的应用。
Rev Esp Cardiol (Engl Ed). 2021 Jan;74(1):114-115. doi: 10.1016/j.rec.2020.08.009. Epub 2020 Aug 28.
5
Association of chronic anticoagulant and antiplatelet use on disease severity in SARS-COV-2 infected patients.慢性抗凝和抗血小板药物使用与新型冠状病毒肺炎（SARS-CoV-2）感染患者疾病严重程度的关联。
J Thromb Thrombolysis. 2021 Aug;52(2):476-481. doi: 10.1007/s11239-021-02383-w. Epub 2021 Feb 1.
6
In critically ill patients with COVID-19, antiplatelet therapy did not increase organ support-free days at 21 d.在 COVID-19 重症患者中，抗血小板治疗并未增加 21 天的无器官支持天数。
Ann Intern Med. 2022 Jul;175(7):JC80. doi: 10.7326/J22-0046. Epub 2022 Jul 5.
7
Anticoagulant or antiplatelet use and severe COVID-19 disease: A propensity score-matched territory-wide study.抗凝或抗血小板药物的使用与重症 COVID-19 疾病：一项倾向评分匹配的全地区研究。
Pharmacol Res. 2021 Mar;165:105473. doi: 10.1016/j.phrs.2021.105473. Epub 2021 Jan 30.
8
Risk and Benefit of Antiplatelet Therapy in COVID-19 Patients with Cancer and Thrombocytopenia: Letter to the Editor.抗血小板治疗对合并癌症和血小板减少症的COVID-19患者的风险与益处：致编辑的信
Cancer Invest. 2021 Mar;39(3):217-218. doi: 10.1080/07357907.2020.1871485. Epub 2021 Jan 14.
9
Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19.COVID-19 住院患者入院前抗血栓治疗对疾病严重程度和死亡率的影响。
J Thromb Thrombolysis. 2022 Jan;53(1):96-102. doi: 10.1007/s11239-021-02507-2. Epub 2021 Jun 17.
10
Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study.强化血小板抑制治疗可改善严重 COVID-19 合并高凝状态患者的低氧血症：一项病例对照、概念验证研究。
Pharmacol Res. 2020 Aug;158:104950. doi: 10.1016/j.phrs.2020.104950. Epub 2020 May 23.
Zotero 插件